Negative Reports Given by Sahm Adrangi of Kerrisdale Capital Management

Many investors have become successful in the stock market. This involves buying and selling of company shares listed in the stock market. It is one of the best investments giving investors huge returns within a short period. Sahm Adrangi is one of the investors and has helped many investors with investment tips that enable them make profits. He founded Kerrisdale Capital Management way back in 2009 and has helped the company grow significantly. The company specializes in investment management.

Kerrisdale Capital Management and Sahm Adrangi focus on research to establish shares that are doing well in the stock market. After thorough investigation, he releases reports to the public. He focuses his research on all companies ranging from real estate firms to online marketing companies listed in the stock market. He has gained experience throughout his career. He has worked at Chanin Capital Partners, Longacre Fund Management, and Deutsche Bank. Being a graduate of economics from Yale University has enabled him have an easy time leading Kerrisdale Capital Management.

  1. Joe Company is one of the real estate companies doing well in the stock market. Sahm Adrangi has released a negative report about the company. Its share prices are extremely high, and many people are tempted to buy the shares. According to Kerrisdale and Sahm, the company’s shares are overvalued and a time is coming for the prices to go down.

Sahm Adrangi has reported about an online marketing company; QuinStreet, Inc. Themarketing Company is generating revenue from a flawed business model that cannot be trusted. In fact, it is getting revenue when users click links and fill out forms. Currently, its shares are doing well, and Sahm is confident that the shares prices will go down soon as the firm has no proper business structures that can make the business sustainable. Also, Sahm Adrangi has given a negative report about Proteostasis Therapeutics which is a biopharmaceutical company at the development stage. The company relies on one drug; PTI-428 which Sahm and Kerrisdale are sure is ineffective in cystic fibrosis treatment.

www.futuresmag.com/author/sahm-adrangi